How to take Ponatinib

Ponatinib (Ponatinib) treatmentChronic myeloid leukemia (CP-CML) starts with a dose of 45 mg, taken orally once a day. When ≤1% BCR-ABL1IS is reached, it is reduced to 15 mg, taken orally once a day. In patients whose response disappears, the dose of ponatinib can be readjusted to the previously tolerated dose of 30 mg or 45 mg orally once daily. Continue ponatinib until no response to re-increasing dose or until toxicity is unacceptable. If no hematologic response occurs within 3 months, consider discontinuing ponatinib.

The optimal dose of ponatinib for the treatment of accelerated phase (AP) or blast phase (BP) chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) has not been determined. The recommended starting dose of ponatinib is 45 mg orally once daily. Consider reducing the dose of ponatinib in patients with accelerated-phase (AP) CML who have achieved a major cytogenetic response. Continue ponatinib until response resolves or unacceptable toxicity develops. If there is still no response after 3 months, consider discontinuing ponatinib.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.